🔗 Share this article

As America continues making unprecedented changes to its vaccine guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on Covid vaccinations in the pandemic and has focused upon possible fatalities following COVID-19 vaccination in her short position at the Food and Drug Administration.

Planned Changes to Pediatric Vaccine Schedule

Health officials planned to announce sweeping changes to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the global community with insufficient data for benefit. The planned update has been postponed until the next year.

Rather than the director of the vaccine center, Høeg is scheduled to speak at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to run the center this year.

A New Direction at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood immunization guidelines in the US to become more like Denmark, a nation with comprehensive healthcare and a citizenry approximately the population of Wisconsin’s.

So far public appearances, she has continued to focus on vaccination policy – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Qualifications

Høeg has little discernible experience in medication creation, oversight or administrative roles, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for leading the CDER, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in leading a sizeable institution. She is not an expert in industry regulation.”

Past commissioners of the center would “grasp laws and regulations and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who headed the center have had.”

The drug center has an immense workload at the FDA, she stated.

“Everybody just focuses on the innovative therapies, but the generic program approves thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one must be managed,” she said. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a major management element to the job, which manages over 5,000 personnel. “It is a huge administrative position, if you do it right,” Woodcock concluded.

Response and Controversial Programs

Regarding questions about Høeg’s credentials and whether this selection signifies more teamwork among agency officials on immunizations, a spokesperson stated that the “questions are based on inaccurate assumptions”.

“Her resume aligns with the duties of her position,” the official stated, noting the time Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's new expedited review system, a controversial rapid drug-approval program that apparently worried her preceding directors. “How are these drugs being selected for this voucher program? Who takes the calls?” Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, except for immunizations.”

Public Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if troubling, history, critics have noted. She released a research paper using unconfirmed public submissions to estimate the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the incoming administration included altering rules for recently developed shots and halting “non-essential” immunizations, she remarked following the vote on a audio program. At the FDA, Høeg has reportedly proposed excluding young men from obtaining COVID-19 vaccines.

“She is an thorough ideologue who starts off with her preconceived notions and reverse-engineers to retrofit the science in a very misleading, untruthful way,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|